Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-α are upregulated in patients with malignancy-associated hypercoagulable state:: Pathophysiologic implications

被引:8
作者
Fareed, D [1 ]
Iqbal, O [1 ]
Tobu, M [1 ]
Hoppensteadt, A [1 ]
Fareed, J [1 ]
机构
[1] Loyola Univ, Med Ctr, Hemostasis & Thrombosis Res Labs, Dept Pathol & Pharmacol, Maywood, IL 60153 USA
关键词
nitric oxide; tumor necrosis factor-alpha; C-reactive protein; hypercoagulable state; malignancy;
D O I
10.1177/107602960401000408
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Endogenous generation of nitric oxide (NO) plays an important role in the regulation of cardiovascular and inflammatory responses. This mediator is synthesized by a family of enzymes collectively known as NO synthase. Several isoforms of this enzyme have been identified and can be grouped as constitutive or inducible. Increased production of NO is reported in several inflammatory disorders, such as sepsis, arthritis, thrombotic thrombocytopenic purpura (TTP)), and antiphospholipid syndrome. In addition, NO upregulates cyclo-oxygenase-2 and synthesis of several other inflammatory cytokines. Inflammation and thrombotic complications are usually associated with malignancy. Earlier reports indicate the upregulation of tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and tissue factor (TF) in patients with malignancy. To determine the relationship between inflammatory cytokines and NO in cancer patients with hypercoagulable states, baseline plasma samples from 160 patients with confirmed malignancy and hypercoagulable state were analyzed for NO levels. A chemical method based on a chemiluminescent reaction between NO and ozone using a highly sensitive gas phase NO analyzer was used. CRP, TF, and TNF-alpha were measured using enzyme-linked immunosorbent assay methods. Of the 160 patients who were plasma tested, the baseline NO levels ranged from 13.7 to 98.6 muM (63.1 +/- 15.9 muM, mean +/- SD) in contrast to age-matched control, which ranged from 9.1 to 34.6 muM (19.8 +/- 6.2 muM, mean +/- SD, n = 138). Cancer patients also showed marked variations in the NO levels. Eighteen of 60 cancer patients exhibited greater than 60 muM NO levels. The CRP, TNF-a and TF were also significantly elevated. A correlation between CRP (r(2) = 0.73) and NO levels was noted in cancer patients with hypercoagulable state. These data suggest that the pathogenesis associated with malignancy/hypercoagulable state is associated with an inflammatory component. In addition, the observed hemodynamic changes in some of the cancer patients may be due to increased NO production.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 25 条
[1]
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor [J].
Abe, K ;
Shoji, M ;
Chen, J ;
Bierhaus, A ;
Danave, I ;
Micko, C ;
Casper, K ;
Dillehay, DL ;
Nawroth, PP ;
Rickles, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8663-8668
[3]
Tissue factor pathway inhibitor release induced by defibrotide and heparins [J].
Cella, G ;
Sbarai, A ;
Mazzaro, G ;
Motta, G ;
Carraro, P ;
Andreozzi, GM ;
Hoppensteadt, DA ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2001, 7 (03) :225-228
[4]
Nitric oxide and cancer [J].
Chhatwal, VJS ;
Moochhala, SM ;
Chan, STF ;
Ngoi, SS .
MEDICAL HYPOTHESES, 1996, 46 (01) :21-24
[5]
ABERRANT EXPRESSION OF NITRIC-OXIDE SYNTHASE IN HUMAN POLYPS, NEOPLASTIC COLONIC MUCOSA AND SURROUNDING PERITUMORAL NORMAL MUCOSA [J].
CHHATWAL, VJS ;
NGOI, SS ;
CHAN, STF ;
CHIA, YW ;
MOOCHHALA, SM .
CARCINOGENESIS, 1994, 15 (10) :2081-2085
[6]
Nitric oxide-induced expression of C-reactive protein in islet cells as a very early marker for islet stress in the rat pancreas [J].
Fehsel, K ;
Plewe, D ;
Kolb-Bachofen, V .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 1997, 1 (03) :254-262
[7]
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyI-L-arginine hydrochloride (546C88), in patients with septic shock [J].
Grover, R ;
Zaccardelli, D ;
Colice, G ;
Guntupalli, K ;
Watson, D ;
Vincent, JL .
CRITICAL CARE MEDICINE, 1999, 27 (05) :913-922
[8]
Horie S, 2002, THROMB HAEMOSTASIS, V87, P80
[9]
Role of nitric oxide in tumour progression with special reference to a murine breast cancer model [J].
Jadeski, LC ;
Chakraborty, C ;
Lala, PK .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2002, 80 (02) :125-135
[10]
Kaiser B, 2001, EXPERT OPIN INV DRUG, V10, P1925